Carvedilol for prevention of restenosis after directional coronary atherectomy: Final results of the European Carvedilol Atherectomy Restenosis (EUROCARE) trial

Circulation

Volumn 101, Issue 13, 2000, Pages 1512-1518

  Serruys, Patrick W ^a   Foley, David P ^b   Höfling, Berthold ^b   Puel, Jacques ^b   Glogar, Helmut D ^b   Seabra Gomes, Ricardo ^b   Goicolea, Javier ^b   Coste, Pierre ^b   Rutsch, Wolfgang ^b   Katus, Hugo ^b   Bonnier, Hans ^b   Wijns, William ^b   Betriu, Amadeo ^b   Hauf Zachariou, Ulrike ^b   Van Swijndregt, Eline Montauban ^b   Melkert, Rein ^b   Simon, Rudiger ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Angiography; Antioxidants; Atherectomy; Carvedilol; Prevention; Restenosis; blocker

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; MULTIVITAMIN; PLACEBO; PROBUCOL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; ARTERY DIAMETER; ARTICLE; ATHERECTOMY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0034603769     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.13.1512     Document Type: Article

References (26)

1. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty, part I: the search for the Holy Grail? Drugs. 1993;46:18-52.
2. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study: a multicenter randomized double-blind placebo-controlled trial. Circulation. 1992;86: 100-110.
3. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es G-A, Pfister PJ, on behalf of the FLARE study group. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis trial. Eur Heart J. 1999;20:58-69.
4. DeMaio SJ, King SB, Lembo NJ, Roubin GS, Hearn JA, Bhagavan HN, Sgoutas DS. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Nutr. 1992;11:68-73.
5. Tardif JC, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, De Guisse P, for the multivitamins and probucol study group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997;337:365-372.
6. Côté G, Tardif JC, Lespérance J, Lambert J, Bourassa M, Bonan R, Gosselin G, Joyal M, Tanguay JF, Nattel S, Gallo R, Crépeau J. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation. 1999;99:30-35.
7. Ruffolo RR, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease and congestive heart failure. Cardiovasc Drugs Ther. 1997;11:247-256.
8. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Londen C, Arleth A, Porte G, Ruffolo RR, Feuerstein GZ. Carvedilol, a novel cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neo-intimal formation following vascular injury. Proc Natl Acad Sci U S A. 1993;90:6189-6193.
9. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 1993;21:221-227.
10. Douglas SA, Vickery-Clark LM, Louden C, Ruffolo RR, Feuerstein GZ, Ohlstein EH. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Res Commun. 1994;5(1):65-72.
11. Yue T-L, McKenna PJ, Lysko PG, Gu JL, Lysko KA, Ruffolo RR, Feuerstein GZ. A metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol. 1994;251:237-243.
12. Yue TL, McKenna PJ, Lysko PG, Ruffolo RR, Feuerstein GZ. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis. 1992;97: 209-216.
13. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein GZ. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
14. Umans V, Hermans W, Foley DP, Strikwerda S, van den Brand M, de Jaegere P, de Feyter PJ, Serruys PW. Restenosis after directional coronary atherectomy and balloon angioplasty: comparative analysis based on matched lesions. J Am Coll Cardiol. 1993;21:1382-1390.
15. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler GP, Berdan LG, Hinohara T, Califf RM. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med. 1993;329:221-227.
16. Foley DP, Melkert R, Umans VA, de Jaegere PP, Strikwerda S, de Feyter PJ, Serruys PW. Differences in restenosis propensity of devices for transluminal coronary intervention: a quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. Eur Heart J. 1995;16:1331-1346.
17. Violaris AG, Serruys PW. Randomized trials: registries or experience-based common sense? In Ellis SG, Holmes DR, eds. Strategies for Coronary Intervention: A Practical Approach. Baltimore, Md: Williams & Wilkins; 1995:190-204.
18. Hermans WR, Foley DP, Rensing BJ, Rutsch W, Hendrickx G, Danchin N, Mast G, Hanet C, Lablanche JM, Rafflenbeul W. Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty. Am J Cardiol. 1993;72:14-20.
19. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol. 1996;27:532-538.
20. Wantanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of carvedilol on nitrate tolerance: a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol. 1998;32:1201-1206.
21. Mintz GS, Popma JJ, Picard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94: 35-43.
22. Kimura T, Kaburagi S, Tamura T, Yokoi H, Nakagawa Y, Yokoi H, Hamasaki N, Nosaka H, Nobuyoshi M, Mintz GS, Popma JJ, Leon MB. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation. 1997;96:475-483.
23. von Birgelen C, Mintz GS, de Vrey EA, de Feyter PJ, Kimura T, Popma JJ, Nobuyoshi M, Serruys PW, Leon MB. Successful directional atherectomy of de novo coronary lesions assessed with three-dimensional intravascular ultrasound and angiographie follow-up. Am J Cardiol. 1997; 80:1540-1545.
24. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology; clues for development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
25. Baim DS, Cutlip DE, Sharma SK, Ho KKL, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, Lansky AJ, Popma JJ, Kuntz RE. Final results of the balloon vs optimal atherectomy trial (BOAT). Circulation. 1997;97:322-331.
26. Simonton CA, Leon MB, Baim DS, Hinohara T, Kent KM, Bersin RM, Wilson BH, Mintz GS, Fitzgerald PJ, Yock PG, Popma JJ, Ho KKL, Cutlip DE, Senerchia C, Kuntz RE. Optimal directional coronary atherectomy final results of the optimal atherectomy restenosis study (OARS). Circulation. 1998;97:332-339.